Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity
NCT05556512 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- October 11, 2022
- Completion date
- October 31, 2027
- Enrollment
- 15,374 (actual)
- Sites
- 671
Conditions
As the registry lists them; a condition with its own page is linked.